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RESEARCH ARTICLE
Astrocyte-specific regulation of hMeCP2 expression in Drosophila
David L. Hess-Homeier1, Chia-Yu Fan3,4, Tarun Gupta2, Ann-Shyn Chiang4 and Sarah J. Certel1,2,*
ABSTRACT
Alterations in the expression of Methyl-CpG-binding protein 2
(MeCP2) either by mutations or gene duplication leads to a wide
spectrum of neurodevelopmental disorders including Rett
Syndrome and MeCP2 duplication disorder. Common features of
Rett Syndrome (RTT), MeCP2 duplication disorder, and
neuropsychiatric disorders indicate that even moderate changes
in MeCP2 protein levels result in functional and structural cell
abnormalities. In this study, we investigated two areas of MeCP2
pathophysiology using Drosophila as a model system: the effects of
MeCP2 glial gain-of-function activity on circuits controlling sleep
behavior, and the cell-type specific regulation of MeCP2 expression.
In this study, we first examined the effects of elevated MeCP2 levels
on microcircuits by expressing human MeCP2 (hMeCP2) in
astrocytes and distinct subsets of amine neurons including
dopamine and octopamine (OA) neurons. Depending on the cell-
type, hMeCP2 expression reduced sleep levels, altered daytime/
nighttime sleep patterns, and generated sleep maintenance deficits.
Second, we identified a 498 base pair region of the MeCP2e2
isoform that is targeted for regulation in distinct subsets of
astrocytes. Levels of the full-length hMeCP2e2 and mutant RTT
R106W protein decreased in astrocytes in a temporally and spatially
regulated manner. In contrast, expression of the deletion D166
hMeCP2 protein was not altered in the entire astrocyte population.
qPCR experiments revealed a reduction in full-length hMeCP2e2
transcript levels suggesting transgenic hMeCP2 expression is
regulated at the transcriptional level. Given the phenotypic
complexities that are caused by alterations in MeCP2 levels, our
results provide insight into distinct cellular mechanisms that control
MeCP2 expression and link microcircuit abnormalities with defined
behavioral deficits.
KEY WORDS: MeCP2, Rett Syndrome, Sleep, Astrocytes,
Drosophila
INTRODUCTION
Methyl-CpG-binding protein 2 (MeCP2) is one of the most
dosage-sensitive genes involved in neuronal functional integrity.
It is thought to perform a complex role in the cell including
coordinating chromatin remodeling, RNA processing, and
promoter repression or activation, depending on the molecular
context (Adkins and Georgel, 2011; Na and Monteggia, 2011;
Samaco and Neul, 2011). Altered levels of MeCP2 either through
loss-of-function mutations (Rett Syndrome (RTT)) or increased
protein levels due to gene duplication or triplication (MeCP2
Duplication Syndrome) (Amir et al., 1999; Ramocki et al., 2010),
results in dramatic phenotypes including mild to profound
intellectual disabilities, motor dysfunction, features of autism,
stereotyped hand movements, recurrent respiratory infections, and
sleep disturbances, and are known collectively as MeCP2 spectrum
disorders (MSD). Overexpression of MeCP2 via transgenic mouse
studies or in patients with MeCP2 Duplication Syndrome link core
behavioral aspects of Autism Spectrum Disorder (ASD) directly to
MeCP2 cellular effects and expand the clinical relevance of
understanding MeCP2 function (Coutinho et al., 2007; Neul, 2012;
Ramocki et al., 2009). In addition, alterations in MeCP2 expression
levels may manifest in neuropsychiatric conditions including
juvenile onset schizophrenia and bipolar disease with mental
retardation depending on the type of mutation or the pattern of X
chromosome inactivation (Gonzales and LaSalle, 2010; Ramocki
et al., 2009). These findings indicate that maintaining MeCP2
levels in a narrow range is a critical component of proper nervous
system development and overall brain function.
Levels of MeCP2 are regulated spatio-temporally in the human
brain with each cell-type expressing a distinct amount (Han et al.,
2013; Shibayama et al., 2004; Skene et al., 2010). MeCP2
expression is highest in neurons yet recent studies indicate
wildtype levels in glia are also essential for maintaining cellular
and network homeostasis. Cultured MeCP2-deficient astrocytes
exhibit striking differences in gene expression, growth rate,
cytotoxic effects, microtubule dynamics, and glutamate (Glu)
clearance that may influence the onset and progression of RTT
(Okabe et al., 2012). The significance of these cellular and
structural consequences of altered MeCP2 glial expression is
apparent as transplantation of wildtype microglia can arrest
multiple aspects of disease pathology exhibited in a MeCP2-null
mouse (Derecki et al., 2012). Although just as clinically relevant,
the consequences of high MeCP2 levels in glia are less
understood.
In this study, we used Drosophila as a model system to first
examine the effects of elevated MeCP2 levels on sleep-related
microcircuits by expressing human MeCP2e2 (hMeCP2) in
astrocytes and distinct subsets of amine neurons including
dopamine and octopamine (OA) neurons. The basic cellular
properties of human MeCP2 are maintained upon expression in
Drosophila including chromatin association, interactions with
human chromatin remodeling gene homologs, and post-
translational modifications (Cukier et al., 2008; Vonhoff et al.,
2012) which suggests, on a molecular basis, at least a subset of
hMeCP2 functional capabilities are preserved. In addition,
proteins containing a methyl-CpG-binding domain (MBD) are
conserved from flies to humans (Hendrich and Tweedie, 2003;
Hu et al., 2006) and hMeCP2-expression causes defects in
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neuronal structure and motor behavior (Vonhoff et al., 2012). We
examined the sleep behavior of males expressing hMeCP2 in
astrocytes and for comparison, in distinct subsets of amine neurons
including dopamine and octopamine (OA) neurons. hMeCP2
expression reduced sleep levels, altered daytime/nighttime sleep
patterns, and generated difficulties in maintaining sleep and
initiating sleep. Each parameter was uniquely affected depending
on the cell-type expressing hMeCP2.
As the number of neuronal and non-neuronal cell-types and
molecular targets of MeCP2 increases, the consideration of potentially
regulating MeCP2 expression itself becomes of great interest. In a
second set of experiments examining the transgenic expression of
MeCP2, we found full-length hMeCP2 (hMeCP2FL) and RTT
R106W protein levels decreased in glial subsets in a temporally and
spatially regulated manner. This result was specific to astrocytes as
hMeCP2 levels were not altered in amine neurons. Further analyses
revealed that astrocytes expressing the hMeCP2D166 allele maintain
detectable protein levels indicating this 498 base pair region contains a
site that may be targeted by a cell-specific endogenous factor.
Quantification of glial number indicated hMeCP2-expressing
astrocytes are not dying but rather the reduction of hMeCP2 levels
is via a transcriptional mechanism. Taken together, our results address
aspects of MeCP2 cell-specific function and regulation by
demonstrating astrocyte expression alters the output of neuronal
sleep-related circuitry and hMeCP2 protein levels are regulated
through a novel site located in the n-terminus.
RESULTS
Astrocyte-expression of hMeCP2 alters sleep parameters
Reciprocal interactions between glia and neurons are essential for
many critical brain functions and astrocytes, in particular, are
involved in the control of multiple neuronal activities (Bekar et al.,
2008; Fillenz et al., 1999; Perea and Araque, 2007). Drosophila
astrocyte-like cells (termed cortex glia) exhibit similarities to their
mammalian counterparts including morphologically as large, star-
shaped cells with extensive processes that surround neuronal cell
bodies (Fig. 1A), and functionally with the expression of
conserved molecular markers such as the high-affinity excitatory
amino acid transporters (EAATs) (Doherty et al., 2009; Freeman
and Doherty, 2006; Soustelle et al., 2002). Recent studies indicate
that the loss of MeCP2 in glia can exert a non-cell-autonomous
negative effect on neighboring neurons (Lioy et al., 2011;
Maezawa and Jin, 2010; Maezawa et al., 2009), however less is
known about potential neuron functional changes due to elevated
levels of glial MeCP2 expression. To test if astrocytic MeCP2
expression non-cell autonomously alters neuron function, we
utilized Drosophila as an in vivo model system and examined sleep
as a relevant behavioral representation of circuit dysfunction.
Sleep disorders are prevalent among children with MeCP2
spectrum disorders and are characterized by delays in the onset of
sleep, alterations in total sleep, and frequent wakings resulting in
fragmented sleep (Cortesi et al., 2010; Piazza et al., 1990;
Souders et al., 2009; Young et al., 2007). In the broadest sense,
sleep is defined as a period of inactivity accompanied by an
increase in arousal threshold and, if disrupted, is followed by a
period of sleep rebound (Hendricks and Sehgal, 2004; Huber
et al., 2004). This definition is also applied to genetically simple
organisms like C. elegans and Drosophila. Two critical aspects of
sleep, the timing of sleep and the length/quality of sleep (Borbély,
1982) are also components of the fruit fly sleep-like state.
Using the Gal4-UAS targeted gene expression system and
previously characterized transgenic lines (Cukier et al., 2008)
Fig. 1. Sleep and expression levels are altered in adult flies
expressing hMeCP2 in astrocytes. (A) An individual Drosophila
astrocyte visualized by CD8:GFP expression in a UAS-CD8:GFP/alrm-
Gal4 adult brain. (B) The Gal4/UAS bipartite system drives transgenic
hMeCP2 expression in astrocytes via alrm-Gal4. All alrm-Gal4 progeny
contained both the alrm-Gal4#3 and alrm-Gal4#2 transgenes. (C,D) The
minutes of sleep over a 24 hour period covering a 10 day span from
individual control males (alrm-Gal4/+,alrm-Gal4/+, UAS-hMeCP2FL/+,
or alrm-Gal4/+;alrm-Gal4/UAS-EGFP) and experimental (alrm-Gal4/+;
alrm-Gal4/UAS-hMeCP2FL) males. (C) Eduction graph displaying 12 hour
night (black bar) and 12 hour day (white bar) periods in control and
experimental males. (D) Males expressing hMeCP2FL in astrocytes
exhibited a decrease in sleep during the day-to-night transition and
through hours 22–24 as compared to controls (F: 20.122, P,0.001,
d51.458; one-way ANOVA of bootstrapped residuals; Nrep550,000; d 5
effect size; pairwise comparisons indicate significant differences in all
control-experimental group pairs) (arrow in panel C). (E–E0) Astrocytes in
control adult brain expressing nuclear dsRed in an alrm-Gal4/UAS-
dsRed;alrm-Gal4/+ progeny. (E9) Nuclear-labeled astrocytes from the
central brain projected onto a standard Drosophila brain representation.
(E0) Quantification of astrocytes located in the central brain region in
control brains (alrm-Gal4/UAS-dsRed;alrm-Gal4/+). (F–F0) Astrocytes
expressing hMeCP2FL in experimental alrm-Gal4/+;alrm-Gal4/UAS-
hMeCP2FL progeny. hMeCP2 is detected by immunofluorescence using a
rabbit hMeCP2 antibody (green, Cell Signaling). (F9) Central brain
hMeCP2FL-labeled astrocytes projected onto a standard Drosophila brain
representation. (F0) Quantification of astrocytes expressing detectable
hMeCP2FL in alrm-Gal4/+;alrm-Gal4/UAS-hMeCP2FL experimental
progeny. Scale bar represents 50 mm.
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(Fig. 1B), we asked if sleep circuitry output is altered in adults
expressing hMeCP2 in astrocytes through the astrocytic leucine-
rich repeat molecule (alrm)-Gal4 line (Doherty et al., 2009) (alrm-
Gal4;alrm-Gal4/UAS-hMeCP2FL as compared to individual
control groups (alrm-Gal4;alrm-Gal4/+ and UAS-hMeCP2FL/+)
(Fig. 1C,D). Using a standard automated behavioral-based system
(Ho and Sehgal, 2005), we quantified total sleep, sleep patterns,
and sleep fragmentation. The total time spent in sleep during a 24-
hour period was significantly reduced in flies expressing hMeCP2
through the alrm-Gal4 line compared to controls with the reduction
occurring immediately after the day:evening transition (Fig. 1C,D,
ZT12-15; supplementary material Fig. S1A,B). However, hMeCP2
expression in astrocytes did not result in fragmented sleep bouts
(supplementary material Fig. S1C), nor do experimental flies
lose rhythmicity in constant dark (DD) conditions or alter
indicators of clock function such as rhythmicity and period (Tau)
(supplementary material Fig. S1D–F; Table S1). Males expressing
hMeCP2 in octopamine and dopamine neurons also displayed
temporally restricted sleep reductions, which occurred in separate
distinct time frames (T.G. and S.J.C., unpublished observations).
These results suggest the expression of hMeCP2 in astrocytes and
neurons can induce distinct alterations in sleep circuitry function in
a cell-type specific manner.
hMeCP2 expression in reduced in a subset of Drosophila
astrocytes
To verify the functionality of the individual genetic components,
we examined the transgenic expression levels of hMeCP2 in amine
neurons and astrocytes. hMeCP2 expression in adult octopamine or
dopamine neurons did not change (supplementary material Fig.
S2), however a significant reduction or absence in hMeCP2 protein
levels in astrocytes was observed. Similar to the widespread
distribution in the vertebrate brain, Drosophila astrocytes can be
found throughout the adult CNS as visualized by expression of a
nuclear-tagged red fluorescent protein (UAS-dsRed) driven through
the alrm-Gal4 driver (Fig. 1B,E). Results from individual
preparations of were superimposed on a standard Drosophila
brain (Fig. 1E9) and the number of dsRed-positive astrocytes
averaged 1547 cells/brain 6 40 (6 s.e.m.) (Fig. 1E0). When we
utilized the same astrocyte(alrm)-Gal4 driver to produce hMeCP2
in all astrocytes, hMeCP2 protein was detected by antibody
labeling in only a small number of astrocytes (290623 (6 s.e.m.))
(Fig. 1F,F9,F0).
Transgenically all astrocytes should be capable of expressing
hMeCP2 in the same manner as the dsRed reporter. To determine if
astrocytes that have the competence to express hMeCP2 are still
present, progeny carrying the dsRed reporter, the hMeCP2
transgene, and the alrm-Gal4 driver were generated. The
full complement of dsRed-positive astrocytes is visible in
UAS-dsRed;alrm-Gal4;alrm-Gal4/UAS-hMeCP2FL adult brains
(Fig. 2A,C), however hMeCP2 protein is not detectable in the
majority of astrocytes in regions including the protocerebrum,
mushroom bodies, and antennal and optic lobes (Fig. 2A,B).
Quantification of cell number indicates 1232615 (6 s.e.m.)
astrocytes expressing dsRed are present and approximately one-
fourth co-express detectable levels of hMeCP2 (348631 (6
s.e.m.)) (Fig. 2D). The reduction in hMeCP2-positive cells does
not occur in a uniform manner; rather detectable hMeCP2 levels
are consistently visible in astrocytes within the suboesophageal
ganglion (SOG) a region that receives taste and contact
pheromonal input (Miyazaki and Ito, 2010; Stocker, 1994).
To verify that the absence of hMeCP2-expression is not due to
insufficient antibody penetration, we substituted the UAS-dsRed
transgene with a UAS-nuclearLacZ transgene (alrm-Gal4;
UAS-nucLacZ/UAS-hMeCP2FL). Using antibodies against b-
galactosidase (b-gal) and MeCP2, lacZ production was easily
visible throughout the Drosophila central brain even in astrocytes
without detectable hMeCP2 expression (supplementary material
Fig. S3). The absence of detectable hMeCP2 protein is not due to
a limiting amount of the Gal4 transcriptional activator as the lack
Fig. 2. The alrm-Gal4 population of astrocytes is
present in hMeCP2FL-expressing brains. (A–C) Adult
brain co-expressing hMeCP2FL and dsRed in astrocytes
(UAS-dsRed/alrm-Gal4;alrm-Gal4/UAS-hMeCP2FL).
hMeCP2FL expression is reduced or not detectable in a
substantial number of astrocytes (B,D) that co-express
dsRed (C,D). (D) Quantification of astrocytes expressing
detectable hMeCP2FL in UAS-dsRed/alrm-Gal4;alrm-
Gal4/UAS-hMeCP2FL progeny. Scale bars represent
50 mm. (E–G) hMeCP2R106W expression is reduced or
not detectable in alrm-Gal4 expressing astrocytes in a
large part of the adult brain including the protocerebrum
(arrow) at 5 (E) or 15 (F) days post-eclosion.
(G) Schematic representation of the single point mutation
in the MBD of the RTT allele hMeCP2R106W.
RESEARCH ARTICLE Biology Open (2014) 000, 1–9 doi:10.1242/bio.20149092
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or reduction of hMeCP2 is visible in progeny with one or two
copies of the alrm-Gal4 driver (supplementary material Fig. S3).
At this point, our data indicates that despite the functionality of
the Gal4 driver, hMeCP2 protein is absent or reduced in subsets
of astrocytes that contain the transgenic constructs to express
hMeCP2. Our control experiments provide reproducible
quantification of glial number and identification of the entire
astrocyte population with either a fluorescent or antibody-
visualized protein. With these results, our focus shifted from
examining the potential cellular or circuitry changes as a
consequence of hMeCP2 expression to investigating cell-
specific regulation of hMeCP2.
RTT hMeCP2R106W expression is reduced in the same
astrocyte subset
To rule out possible UAS-hMeCP2FL transgenic construct defects
that may explain the loss of detectable hMeCP2 protein, we tested
the RTT point mutation hMeCP2R106W transgenic line (UAS-
hMeCP2R106W) (Cukier et al., 2008). The RTT R106W allele is a
missense mutation within the methyl-CpG binding domain that
greatly reduces the protein’s ability to bind DNA (Fig. 2G)
(Yusufzai and Wolffe, 2000). As predicted for a single amino acid
change, expression of hMeCP2R106W in astrocytes (alrm-Gal4/
UAS-hMeCP2R106W,alrm-Gal4) results in the same phenotype as
full-length hMeCP2 expression, namely a reduction in detectable
protein as assayed by antibody labeling in central brain astrocytes
at 5 days post-eclosion (Fig. 2E). hMeCP2R106W expression was
maintained only in suboesophageal ganglia astrocytes in the aging
brain (15 days post-eclosion, Fig. 2F).
The reduction of hMeCP2 is developmentally regulated
In human brains, MeCP2 levels are relatively low during fetal
stages and elevated in postnatal development (Balmer et al.,
2003). To determine if the levels of transgenically produced
hMeCP2 may be developmentally regulated in astrocytes in our
Drosophila model, we first dissected the central nervous system
from hMeCP2-expressing third instar larvae. The third instar
larval period is the final stage of growth and feeding before the
complex tissue reorganization of metamorphosis occurs during
pupation (Hertweck, 1931; Power, 1947; Truman, 1990).
Astrocytes within the central brain of third instar larvae exhibit
co-localization of b-gal and hMeCP2 (alrm-Gal4/UAS-
nucLacZ;alrm-Gal4/UAS-hMeCP2FL) (supplementary material
Fig. S4A–C). An absence of hMeCP2 expression is observed in
astrocytes located in the optic lobe (arrows, supplementary
material Fig. S4A–C) suggesting differences exist in astrocyte
lineages at this stage of larval development.
A developmental transition in hMeCP2 levels is also observed
after larval stages. hMeCP2 expression is visible in all alrm-Gal4
astrocytes throughout the brain of newly-eclosed adults (Fig. 3A).
The striking reduction in detectable hMeCP2 expression as
described in Figs 1 and 2 is visualized by 5 days post-eclosion
with expression of hMeCP2 maintained in SOG astrocytes of
aged (25 day post-eclosion, Fig. 3B) adults. Results from these
experiments suggest the molecular composition of astrocytes
regionally, i.e. within the optic lobe and temporally, i.e. at mature
stages (adult and larval) include a gene product that regulates
hMeCP2 at the transcriptional or translational level.
Due to the multiple proposed cellular targets of hMeCP2, we
next examined if alrm-Gal4;UAS-hMeCP2 cells continued to
express markers consistent with glial differentiation. To identify
subsets of glia, we used an antibody against the homeodomain
protein, Repo (Reversed polarity). Repo plays a key role in glial
development and diversification (Yuasa et al., 2003). Adult CNS
glia (Awasaki et al., 2008) express Repo including astrocytes
labeled in the alrm-Gal4/UAS-nucLacZ;alrm-Gal4 adult brain
Fig. 3. hMeCP2 expression is developmentally regulated and does not
alter glial differentiation. (A) At 1 day post-eclosion, hMeCP2 expression is
detected by immunofluorescence in the majority of alrm-Gal4 expressing
astrocytes. (B) At 5 days post-eclosion, hMeCP2 protein is reduced or not
detectable in astrocytes located outside of the SOG region. (C) The
transcription factor Repo is co-expressed with b-gal in optic lobe astrocytes
(arrow) in alrm-Gal4/UAS-nucLacZ;alrm-Gal4 progeny. (D) hMeCP2-
expressing astrocytes maintain glial differentiation as assayed by Repo
expression in the optic lobe (arrow) and the SOG (arrowhead) in the alrm-
Gal4/+;alrm-Gal4/UAS-hMeCP2FL adult brain. Scale bars represent 50 mm.
(E,E9) Confocal image of the large number of astrocytes labeled by a cell-
membrane GFP reporter in the brain of a control alrm-Gal4/+;alrm-Gal4/
UAS-CD8:GFP adult. (E9) Optical sections of a hs-flp;alrm-Gal4/UAS-
.stop.CD8:GFP;alrm-Gal4/+ control brain at a high magnification showing
a single GFP-expressing astrocyte. (F,F9) hMeCP2FL-expressing
astrocytes labeled with the same cell-membrane GFP reporter in an adult
alrm-Gal4/UAS-CD8:GFP;alrm-Gal4/UAS-hMeCP2FL brain five days post-
eclosion. GFP-expressing astrocytes with or without detectable hMeCP2 (red
nuclear expression) cover the entire brain as in control brains. (F9) Optical
sections from a hs-flp;alrm-Gal4/UAS->stop>CD8:GFP;alrm-Gal4/UAS-
hMeCP2FL brain at high magnification showing a single GFP and hMeCP2FL
-expressing astrocyte. The dense, fine processes observed in control
astrocytes are present in astrocytes expressing hMeCP2FL. Scale bar
represents 50 mm.
RESEARCH ARTICLE Biology Open (2014) 000, 1–9 doi:10.1242/bio.20149092
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(Fig. 3C,D). When the UAS-nucLacZ reporter is replaced with the
hMeCP2 transgene, we observe Repo-labeled astrocytes in the
optic lobe (arrows, Fig. 3C) that are present but do not express
detectable hMeCP2 protein (arrows, Fig. 3D). This result
indicates that astrocytes previously producing hMeCP2 still
maintain a glial state. In addition, we analyzed the morphology of
individual astrocytes expressing GFP or astrocytes expressing
GFP with hMeCP2 as distinct defects in dendritic structure are
observed in Drosophila motor neurons expressing MeCP2
(Vonhoff et al., 2012). At this point, we are unable to compare
the same astrocyte with or without hMeCP2 expression however,
the morphology of individual astrocytic processes from the same
brain region does not appear to be significantly altered by
hMeCP2 expression (Fig. 3E–F0).
hMeCP2D166 expression is detected in the entire
alrm-expressing glia population
Using a third independent transgenic line, we expressed
hMeCP2D166, which lacks the N-terminus including the MBD
(Fig. 4C) (Cukier et al., 2008), via the alrm-Gal4 driver. In
contrast to the region-specific reduction in hMeCP2FL or
hMeCP2R106W expression, the hMeCP2D166 protein is detected
in the entire alrm-Gal4 astrocyte population and is maintained in
the aging brain (Fig. 4A,B). This result indicates that transgenic
expression of hMeCP2 in all alrm-Gal4 astrocytes is possible and
suggests that the N-terminus contains a site that may be targeted
by a cell-specific endogenous factor to transcriptionally or
translationally regulate full-length hMeCP2 expression.
Although astrocytes are often classified as a population of cells,
glial subsets can display diverse molecular and functional profiles
(Matthias et al., 2003; Nimmerjahn, 2009; Regan et al., 2007).
In particular, specific astrocyte populations take up and recycle
the principal neurotransmitter in the brain, glutamate, by
expressing high-affinity, sodium-dependent excitatory amino
acid transporters (EAATs) (Lee and Pow, 2010; Zhou and
Danbolt, 2013). EAAT1 and EAAT2 are expressed in discrete
and partially overlapping subsets of differentiated glia in
Drosophila (Rival et al., 2004; Soustelle et al., 2002). To
demonstrate that a decrease in detectable hMeCP2 protein is
observed in the EAAT1 subset of glial cells and that separate
Gal4 lines are capable of producing the same hMeCP2 reduction
phenotype, we drove hMeCP2FL expression with the EAAT1-
Gal4 driver (Rival et al., 2004). When flies were generated to
contain the dsRed reporter and the hMeCP2 transgene together
with the EAAT1-Gal4 transgene (UAS-dsRed;EAAT1-Gal4/UAS-
hMeCP2FL), we observed a large complement of dsRed-positive
astrocytes, however hMeCP2 protein is detectable at very low
levels or absent in the majority of EAAT1-identified astrocytes
(Fig. 4D,D9). In addition, a reduction or absence of hMeCP2
protein is also observed in a subset of inner-optic chiasm giant
glia cells located in the larval optic lobe (supplementary material
Fig. S5). Taken together, these experiments demonstrate that
combinations of multiple Gal4 drivers and UAS-MeCP2 lines
result in the same reduction of hMeCP2 protein expression
phenotype.
Transcript levels of transgenic hMeCP2FL are reduced
To ask if the potential translational or transcriptional regulation of
hMeCP2 could be overcome by providing more than one
transgenic copy of hMeCP2, progeny were generated that
contained two alrm-Gal4 copies and two hMeCP2 transgenes.
hMeCP2 expression in central brain astrocytes remains
Fig. 4. The hMeCP2D166 allele is expressed
in all astrocytes. (A,B) hMeCP2D166
expression is detected in alrm-Gal4 expressing
astrocytes throughout the brain at 5 (A) or 15
(B) days post-eclosion (alrm-Gal4/UAS-
hMeCP2D166;alrm-Gal4/+). (C) Schematic
representation of the hMeCP2D166 allele
containing a deletion of the N-terminus
including the MBD. hMeCP2D166 expression is
detected by immunofluorescence with the
rabbit hMeCP2 antibody (green, Cell
Signaling). (D,D9) Confocal images of two UAS-
dsRed;EAAT1-Gal4/UAS-hMeCP2FL adult
brains demonstrating hMeCP2FL protein is
largely absent or reduced in the Eaat1 glial
population. Co-expression of dsRed and
hMeCP2FL is maintained in a number of glia in
the optic lobe (arrow) or around the antennal
lobe. Scale bars represent 50 mm.
RESEARCH ARTICLE Biology Open (2014) 000, 1–9 doi:10.1242/bio.20149092
5
B
io
lo
g
y
O
p
e
n
undetectable in the resulting progeny (alrm-Gal4/UAS-
hMeCP2R106W;alrm-Gal4/UAS-hMeCP2FL) (supplementary
material Fig. S4D,E). To examine hMeCP2 transcript levels
directly, total RNA was extracted from the heads of adults
expressing hMeCP2FL (alrm-Gal4;alrm-Gal4/UAS-hMeCP2FL)
or hMeCP2D166 (alrm-Gal4/UAS-hMeCP2D166;alrm-Gal4). We
performed quantitative RT-PCR experiments with primer sets
directed to the last exon or 39 UTR (Fig. 5A). Our results
demonstrate that the levels of full-length hMeCP2 transcripts in
astrocytes are significantly reduced when compared to
hMeCP2D166 transcript levels (Fig. 5B). In contrast, transcript
levels do not change in adults expressing hMeCP2FL versus
hMeCP2D166 in amine neurons (Fig. 5C). Results from these
experiments indicate that the absence of detectable hMeCP2FL
protein in a subset of adult stage astrocytes is likely due to
temporally and spatially-controlled transcript degradation.
Furthermore, the continued expression of hMeCP2D166 protein
production identifies a region that possibly contains sites
important for the targeting and degradation of hMeCP2FL
transcripts.
DISCUSSION
The importance of tightly controlling MeCP2 levels in the human
nervous system has been underscored by numerous studies
encompassing loss-of-function or overexpression conditions.
Loss-of-function mutations in MeCP2 cause Rett Syndrome
while duplications and/or triplications spanning the MeCP2 locus
result in progressive neurological disorders characterized by
autism, motor abnormalities, and seizures (Ben-Shachar et al.,
2009; del Gaudio et al., 2006; Ramocki et al., 2009; Ramocki
et al., 2010; Van Esch et al., 2005). As the discovery of distinct
neuronal and non-neuronal cell-types that contribute to the
various MeCP2-related clinical phenotypes increases, the number
of molecular targets of MeCP2 increases as well. Considering the
critical role of MeCP2 not only during development but also in
maintaining cellular function in adulthood (Castro et al., 2013;
Garg et al., 2013; Luikenhuis et al., 2004; Nguyen et al., 2012;
Olson et al., 2014), MeCP2 regulation whether by transcriptional
control via DNA regulatory elements or post-transcriptional
mechanisms by RNA–protein, RNA–RNA, or RNA–DNA
interactions is likely to continue to expand in complexity and in
importance (Singh et al., 2008).
Here we report on the spatial and temporal post-transcriptional
regulation of human MeCP2 levels in Drosophila astrocytes and
on circuit functional changes due to glial expression. Until
relatively recently, astrocytes, along with other glia cell types,
were believed to be structural cells that function to hold neurons
together. It is now appreciated that astrocytes serve many
functions, including developmental roles during synaptogenesis,
maintenance of the extracellular environment and stabilization of
cell–cell communications in the CNS. In addition, astrocytes are
increasingly recognized as active partners in synaptic function
including regulating basal synaptic transmission and synaptic
efficacy leading to the proposal that normal brain output arises
from the coordinated activity of a network comprising both
neurons and glia (Eyo and Dailey, 2013; McGann et al., 2012;
Navarrete et al., 2013; Perea and Araque, 2010; Sloan and Barres,
2014). A group of recent studies highlight the role of astrocytes in
the modulation of circuit concerned with sleep and sleep-related
rhythmogenesis (Florian et al., 2011; Halassa et al., 2009; Schmitt
et al., 2012). Glial cells regulate slow oscillations, a specific
thalamocortical activity that characterizes non-REM sleep, and
sleep-associated behaviors (Fellin et al., 2012; Halassa et al.,
2010). In our studies, hMeCP2 expression in Drosophila
astrocytes caused a significant decrease in sleep with the
reduction occurring at a specific time point, immediately after
the day:evening transition. How potential cell or non-cell
autonomous morphological or functional defects cause the
distinct deficit in sleep observed in our Drosophila males
expressing hMeCP2 in astrocytes is presently unknown.
However, a recent study determined dendritic structure defects
in motor neurons are caused by MeCP2 expression (Vonhoff
et al., 2012) and as the neurons and circuits that regulate sleep
duration, initiation, and maintenance are well studied in
Fig. 5. hMeCP2FL transcript levels are reduced compared to hMeCP2D166 levels. (A) Primer locations depicted in a schematic representation of hMeCP2
locus. (B) For semi-quantitative RT-PCR experiments, RNA from the heads of adults expressing hMeCP2FL in astrocytes (alrm-Gal4/+;alrm-Gal4/UAS-
hMeCP2FL, green column), and hMeCP2D166 in astrocytes (alrm-Gal4/UAS-hMeCP2D166;alrm-Gal4/+, blue column). Adult alrm-Gal4;UAS-hMeCP2FL flies at
5–10 days post-eclosion showed significant decreases in hMeCP2 transcript levels as compared to age-matched alrm-Gal4;UAS-hMeCP2D166 adults (Mann–
Whitney test, **P,0.05). (C) In comparison, transcript levels were not statistically different in adults expressing hMeCP2FL in octopamine neurons (Tdc2-
Gal4;UAS- hMeCP2FL, green column) compared to age matched controls expressing the hMeCP2D166 in octopamine neurons (Tdc2-Gal4/UAS-hMeCP2D166,
blue column) (Mann–Whitney test, P.0.7). Reactions were performed in quadruplicate for each gene. Rpl32 expression was used as the reference control to
normalize expression between treatment groups (error bars indicate s.e.m.).
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Drosophila, further analysis of these described sleep deficits
should prove fruitful. Results from our sleep paradigm can also be
viewed as the endpoint behavioral representation of synaptic
connectivity and dysfunction of circuits in general, which is a
fundamental theme in neurodevelopmental syndromes including
RTT (Shepherd and Katz, 2011).
Although MeCP2 is ubiquitously transcribed, the expression of
distinct MeCP2 isoforms is developmentally regulated and
heterogeneous in neuronal subpopulations and may be impacted
by DNA methylation patterns at MeCP2 regulatory elements may
impact the differential expression of MeCP2/MeCP2 isoforms in
brain regions (Olson et al., 2014). A series of separate studies
suggest a role of RNAi-induced down-regulation of MeCP2
expression (Jin et al., 2008). In our studies, human MeCP2e2 and
RTT R106W transcript levels significantly decrease in astrocyte
subsets, while expression of the MeCP2D166 allele is not altered.
The region absent in MeCP2D166 contains the MBD domain, a
nuclear localizing signal, and a region designated HMG1, due to
the amino acid composition similarity to high mobility group
(HMG) proteins (Adams et al., 2007; Adkins and Georgel, 2011;
Becker et al., 2013; Ghosh et al., 2010). What types of
evolutionarily conserved cis-regulatory elements are located in
this area of the hMeCP2-coding region? Several studies have
identified microRNA target sites, AU-rich elements, and G-
quadruplexes within the transcribed regions of hMeCP2 (Bagga
and D’Antonio, 2013; Saunders et al., 2010). Many of these DNA
regions influence DNA replication, transcription, and epigenetic
mechanisms (Baral et al., 2013; Belotserkovskii et al., 2013). For
example expression of the microRNA, miR-483-5p, decreased
MeCP2 mRNA levels through the human-specific binding site in
the MeCP2 long 39 UTR (Han et al., 2013). At this point, our
results suggest an endogenous factor expressed in Drosophila
glia, targets a regulatory component or components located
within the first 498 base pair region of hMeCP2. As wildtype
MeCP2 levels in glial cells are essential for proper development
and maturation of the brain, identifying cell-type specific
mechanisms that activate or repress normal levels to achieve a
controlled balance of MeCP2 expression would be useful in
therapeutic considerations.
MATERIALS AND METHODS
The following strains were used in this study: alrm-Gal4#2, alrm-Gal4#3
(Doherty et al., 2009), EAAT1-Gal4 (BL 8849), dTdc2-Gal4 (Cole et al.,
2005), OmbC-Gal4 (Hofmeyer et al., 2008), UAS-MeCP2FL (Cukier
et al., 2008), UAS-MeCP2R106W (Cukier et al., 2008), UAS- hMeCP2D166
(Cukier et al., 2008), UAS-Red Stinger (BL 8545 and BL 8546), UAS-
nucLacZ (BL 3955), hs-flp (BL 8862), UAS-mCD8:GFP (BL 5130),
20XUAS-6XGFP-Myc (BL 52262), and UAS.stop.mCD8:GFP (BL
5007) from the Bloomington Stock Center, Bloomington, IN.
Immunohistochemistry
Brains in Figs 1 and 2 were dissected according to the following protocol.
Brain samples were dissected in phosphate-buffered saline (PBS) and fixed
in 4% paraformaldehyde for 30 min at room temperature. Then, the brain
samples were incubated in PBS containing 1% Triton X-100 and 10%
normal goat serum (PBS-T) and degassed in a vacuum chamber to expel
tracheal air with four cycles (depressurize to ,70 mmHg then hold for
10 min). Next, the brain samples were blocked and penetrated in PBS-T at
4 C̊ overnight and then incubated in PBS-T containing 1:50 mouse 4F3
anti-discs large monoclonal antibody (Developmental Studies Hybridoma
Bank, University of Iowa) and 1:200 rabbit anti-MeCP2 (Cell Signaling
D4F3) at 4 C̊ for two days. After washing in PBS-T three times, the
samples were incubated in PBS-T containing 1:250 biotinylated goat anti-
mouse IgG (Molecular Probes) and 1:500 Alexa Fluor 488 goat anti-rabbit
IgG (Molecular Probes) at 4 C̊ overnight. Next, brain samples were washed
and incubated with 1:500 Alexa Fluor 635 streptavidin (Molecular Probes)
at 4 C̊ overnight. Finally, after extensive washing, the immunolabeled
brain samples were directly cleared in FocusClear (CelExplorer, Taiwan)
for 5 min and then mounted in a drop of MountClear (CelExplorer) and
then imaged under a Zeiss LSM 510 confocal microscope. Each cell body
labeled by both Red Stinger and Alexa Fluor 488 in the central brain was
manually marked with a landmark sphere. The total number of landmark
spheres placed in the central brain was automatically counted with Amira
(Visage Software, San Diego, CA).
Brains in all other figures were dissected according to a separate
protocol. Adult male and female dissected brains were fixed in 4%
paraformaldehyde (Electron Microscopy Sciences) for 25 minutes and
labeled using a modification of protocols previously described (Certel
et al., 2007). The following primary antibodies were used: rabbit anti-
MeCP2 (1:200, Cell Signaling D4F3), mouse anti-MeCP2 (1:1000,
Abcam AB50005), rat anti-CD8 (1:100, Molecular Probes), rabbit
polyclonal anti-b-galactosidase (1:100, Abcam), mouse anti-b-
galactosidase (1:50, Developmental Studies Hybridoma Bank), mouse
8D12 anti-repo (1:20, DSHB), anti-bruchpilot (mAb nc82, 1:30,
Developmental Studies Hybridoma Bank) (Hofbauer et al., 2009), and
monoclonal rabbit anti-GFP (1:200, Molecular Probes). Secondary
antibodies include Alexa Fluor 488-conjugated goat anti-rabbit, Alexa
Fluor 488-conjugated goat anti-rat Alexa Fluor 594-conjugated donkey
anti-mouse, Alexa Fluor 594-conjugated goat anti-rabbit, Alexa Fluor
647-conjugated donkey anti-mouse (Molecular Probes), Images were
collected on an Olympus Fluoview FV1000 laser scanning confocal
mounted on an inverted IX81 microscope and processed using ImageJ
(NIH) and Adobe Photoshop (Adobe, CA).
qPCR
Total RNA from ,50 combined heads was isolated by Tri-Reagent,
(Molecular Research Center, Cincinnati, OH) following manufacturers
protocols. RNA samples were treated using PerfeCTa DNase I kit
(Quanta Biosciences, 95150-01K) according to manufacturer’s protocols.
RNA concentrations were subsequently measured with a ND-1000
nanodrop spectrometer. Reverse transcription was accomplished using
Qscript cDNA supermix (Quanta Biosciences, 95048) according to
manufacturer’s protocols with 200 ng RNA in 10 mL. qPCR reactions
were carried out using 5 mL PerfeCTa SYBR Green SuperMix for iQ
(Quanta Biosciences, 95053-100), 4 mL cDNA diluted 1:5 after reverse
transcription, primers at 561025 ng/ml, and DEPC water to a total
volume of 10 mL.
qPCR reactions were carried out using 5 mL PerfeCTa SYBR Green
SuperMix for iQ (Quanta Biosciences, 95053-100), 80 ng cDNA, primers
at 561025 ng/ml, and DEPC water to a total volume of 10 mL. Reactions
were carried out on an Agilent Stratagene Mx3005P platform. Samples
were first held at 95 C̊ for 10 minutes before forty cycles of 30 seconds
at 95 C̊, 60 seconds at 52 C̊, and 60 seconds at 72 C̊. Reactions were
completed with a final cycle of 60 seconds at 95 C̊, 30 seconds at 55 C̊,
and 30 seconds at 95 C̊. Reactions were performed in quadruplicate for
each gene and genotype. Expression of ribosomal protein L32 (RpL32)
was used as the reference control to normalize expression between
genotypes. Expression levels were calculated using the DDCT method.
Primers used to amplify RpL32 were F: 59ATGCTAAGCTGTC-
GCACAAATG39 and R: 59GTTCGATCCGTAACCGATGT39. To
ensure validity of results, each qPCR experiment was repeated with
different sets of MeCP2 primers. The first set MeCP2 primers was F:
59TTAGTCCCTCAAGCCACCAG39 and R: 59GGACGGAGGAAGG-
GAAAGAA39. The second set of MeCP2 primers was F: 59AACA-
GAGAGGAGCCTGTGGA39 and R: 59-ACTTCTGGCCCTGGTTAGGT39.
Sleep assay
Male pupae were isolated and aged individually for 2–3 days in
16 100 mm borosilicate glass tubes containing standard culture medium
described above. During development and post-eclosion, progeny were
entrained to standard L:D conditions, 12-hr light phase followed by a 12-
hr dark phase, at 25 C̊ and 50% relative humidity. Male adults, age 3–5
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days post-eclosion, were transferred to individual 6565 mm glass tubes
(Trikinetics) containing 15 mm food and a cotton plug on either end.
Flies were allowed a 24-hr period to recover from the CO2
anesthetization necessary for tube transference. The locomotor activity
patterns of individual experimental and control males were recorded by
the Drosophila Activity Monitoring (DAM) system (Trikinetics) for a
period of 10 consecutive days using the 1-min bin acquisition mode. Data
from the first and last day were removed. The resulting activity data was
analyzed using the Counting Macro 5.19.5 (CM) program (R. Allada,
Northwestern University, Evanston, IL). Sleep related parameters
including amount of sleep, latency to sleep, number of sleeping bouts,
length of each bout and waking activity etc. were measured
(Pfeiffenberger et al., 2010). A sleep bout was defined as complete
inactivity for a period of 5 consecutive minutes as in previous studies
(Shaw et al., 2000). Graphpad Prism and Adobe Photoshop were used to
generate graphs.
Statistics
Bootstrap-based resampling procedures v1.3 were used to quantify the
effect of hMeCP2 expression in astrocytes on sleep during ZT12-15
(Howell, 2002). Average amount of sleep per 30 min bin was extracted
from sleep eduction data for ZT12-15. Sample distribution was empirically
determined by random sampling of residuals with replacement and F-
statistic was computed for each of the 50,000 bootstrapped residuals. The
resulting distribution was used to evaluate the likelihood of obtaining an F-
statistic greater than the value obtained from the sample means at 95%
confidence interval. Results were cross-validated with permutation tests
that involve randomization without replacement.
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Kettenmann, H. and Steinhäuser, C. (2003). Segregated expression of
AMPA-type glutamate receptors and glutamate transporters defines distinct
astrocyte populations in the mouse hippocampus. J. Neurosci. 23, 1750-1758.
McGann, J. C., Lioy, D. T. and Mandel, G. (2012). Astrocytes conspire with
neurons during progression of neurological disease. Curr. Opin. Neurobiol. 22,
850-858.
Miyazaki, T. and Ito, K. (2010). Neural architecture of the primary gustatory center
of Drosophila melanogaster visualized with GAL4 and LexA enhancer-trap
systems. J. Comp. Neurol. 518, 4147-4181.
Na, E. S. and Monteggia, L. M. (2011). The role of MeCP2 in CNS development
and function. Horm. Behav. 59, 364-368.
Navarrete, M., Perea, G., Maglio, L., Pastor, J., Garcı́a de Sola, R. and Araque,
A. (2013). Astrocyte calcium signal and gliotransmission in human brain tissue.
Cereb. Cortex 23, 1240-1246.
Neul, J. L. (2012). The relationship of Rett syndrome and MECP2 disorders to
autism. Dialogues Clin. Neurosci. 14, 253-262.
Nguyen, M. V., Du, F., Felice, C. A., Shan, X., Nigam, A., Mandel, G., Robinson,
J. K. and Ballas, N. (2012). MeCP2 is critical for maintaining mature neuronal
networks and global brain anatomy during late stages of postnatal brain
development and in the mature adult brain. J. Neurosci. 32, 10021-10034.
Nimmerjahn, A. (2009). Astrocytes going live: advances and challenges. J.
Physiol. 587, 1639-1647.
Okabe, Y., Takahashi, T., Mitsumasu, C., Kosai, K., Tanaka, E. and Matsuishi, T.
(2012). Alterations of gene expression and glutamate clearance in astrocytes derived
from an MeCP2-null mouse model of Rett syndrome. PLoS ONE 7, e35354.
Olson, C. O., Zachariah, R. M., Ezeonwuka, C. D., Liyanage, V. R. and
Rastegar, M. (2014). Brain region-specific expression of MeCP2 isoforms
correlates with DNA methylation within Mecp2 regulatory elements. PLoS ONE
9, e90645.
Perea, G. and Araque, A. (2007). Astrocytes potentiate transmitter release at
single hippocampal synapses. Science 317, 1083-1086.
Perea, G. and Araque, A. (2010). GLIA modulates synaptic transmission. Brain
Res. Rev. 63, 93-102.
Pfeiffenberger, C., Lear, B. C., Keegan, K. P. and Allada, R. (2010). Processing
sleep data created with the Drosophila Activity Monitoring (DAM) System. Cold
Spring Harb. Protoc. 2010, t5520.
Piazza, C. C., Fisher, W., Kiesewetter, K., Bowman, L. and Moser, H. (1990).
Aberrant sleep patterns in children with the Rett syndrome.Brain Dev. 12, 488-493.
Power, M. E. (1947). A demonstration of the internal structure of the thoracico-
abdominal nervous system of Drosophila. Anat. Rec. 99, 630.
Ramocki, M. B., Peters, S. U., Tavyev, Y. J., Zhang, F., Carvalho, C. M., Schaaf,
C. P., Richman, R., Fang, P., Glaze, D. G., Lupski, J. R. et al. (2009). Autism
and other neuropsychiatric symptoms are prevalent in individuals with MeCP2
duplication syndrome. Ann. Neurol. 66, 771-782.
Ramocki, M. B., Tavyev, Y. J. and Peters, S. U. (2010). The MECP2 duplication
syndrome. Am. J. Med. Genet. A. 152A, 1079-1088.
Regan, M. R., Huang, Y. H., Kim, Y. S., Dykes-Hoberg, M. I., Jin, L., Watkins,
A. M., Bergles, D. E. and Rothstein, J. D. (2007). Variations in promoter
activity reveal a differential expression and physiology of glutamate transporters
by glia in the developing and mature CNS. J. Neurosci. 27, 6607-6619.
Rival, T., Soustelle, L., Strambi, C., Besson, M. T., Iché, M. and Birman,
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